HAYA closes US$5M seed extension led by Humboldt Fund to advance the development of its anti-fibrotic lead program targeting Wisper, a cardiac long non-coding RNA HAYA Therapeutics, SA, a company
-Company previews an integrated suite of solutions, including the new PhenoCyclerâ„¢-Fusion System for unbiased spatial discovery, at unprecedented speeds .